Exhibit 10.1


 


EXCHANGE AGREEMENT


 


by and between


 


HANOVER BANCORP, INC.


 


and


 


CASTLE CREEK CAPITAL PARTNERS VIII, LP


 


Dated as of October 28, 2022


 






     


     


    

 


This EXCHANGE AGREEMENT is
made and entered into as of October 28, 2022 (this “Agreement”) by and between Hanover Bancorp, Inc., a New
York corporation (the “Company”), and Castle Creek Capital Partners VIII, LP, a Delaware limited partnership (the “Investor”).


 


RECITALS


 


A.                   The
Investor is, as of the date hereof, the record and beneficial owner of 700,750 shares (the “Investor Common Shares”)
of the Company’s common stock (the “Common Shares”).


 


B.                    The
Investor desires to purchase an additional 150,000 Common Shares in a private secondary market transaction (the “Purchase”);


 


C.                    The
Company and the Investor desire to exchange (the “Exchange”) 150,000 of the Investor Common Shares (the “Exchanged
Shares”) for shares of the Company’s Series A Preferred Stock, par value $0.01 per share (the “Series A
Preferred Shares”), on the terms and subject to the conditions set forth herein.


 


NOW, THEREFORE, in consideration
of the mutual covenants and agreements contained in this Agreement, the receipt and sufficiency of which are hereby acknowledged, and
intending to be legally bound, the parties hereby agree as follows:


 


ARTICLE I


 


THE CLOSING; CONDITIONS TO THE CLOSING


 


Section 1.1           The
Closing.


 


(a)           The
closing of the Exchange (the “Closing”) will take place remotely via the electronic exchange of documents and signature
pages, as the parties may agree. The Closing shall take place on the date hereof; provided, however, that the conditions set
forth in Sections 1.1(c), (d) and (e) shall have been satisfied or waived, or at such other place, time and date as shall be
agreed between the Company and the Investor. The time and date on which the Closing occurs is referred to in this Agreement as the “Closing
Date.”


 


(b)           Subject
to the fulfillment or waiver of the conditions to the Closing in this Section 1.1, at the Closing (i) the Company will or will
cause the transfer agent for the Series A Preferred Shares (as applicable) to register the Series A Preferred Shares in the
name of the Investor and deliver or cause to be delivered reasonably satisfactory evidence of such registration to the Investor and (ii) the
Investor will deliver the certificate(s) or book-entry shares representing the Exchanged Shares to the Company.


 


(c)           The
respective obligations of each of the Investor and the Company to consummate the Exchange are subject to the fulfillment (or waiver by
the Company and the Investor, as applicable) prior to the Closing of the conditions that (i) any approvals, non-objections or authorizations
of all United States and other governmental, regulatory or judicial authorities (collectively, “Governmental Entities”)
required for the consummation of the Exchange shall have been obtained or made in form and substance reasonably satisfactory to each party
and shall be in full force and effect and all waiting periods required by United States and other applicable law, if any, shall have expired
and (ii) no provision of any applicable United States or other law and no judgment, injunction, order or decree of any Governmental
Entity shall prohibit consummation of the Exchange as contemplated by this Agreement or impose material limits on the ability of any party
to this Agreement to consummate the transactions contemplated by this Agreement.


 


(d)           The
obligation of the Investor to consummate the Exchange is also subject to the fulfillment (or waiver by the Investor) at or prior to the
Closing of each of the following conditions:


 


(i)                 (A) the
representations and warranties of the Company set forth in Article IV of this Agreement shall be true and correct in all material
respects as though made on and as of the date of this Agreement and as of the Closing Date (other than representations and warranties
that by their terms speak as of another date, which representations and warranties shall be true and correct in all material respects
as of such other date) and (B) the Company shall have performed in all material respects all obligations required to be performed
by it under this Agreement at or prior to the Closing;


 






     


     


    

 


(ii)                the
Investor shall have received a certificate signed on behalf of the Company by an executive officer certifying to the effect that the conditions
set forth in Section 1.1(d)(i) have been satisfied; and


 


(iii)               the
Company shall have delivered evidence in book-entry form, evidencing the issuance of the Series A Preferred Shares to the Investor.


 


(e)           The
obligation of the Company to consummate the Exchange is also subject to the satisfaction or waiver, at or prior to the Closing, of the
following conditions:


 


(i)                 (A) the
representations and warranties of the Investor set forth in Article V of this Agreement shall be true and correct in all material
respects as though made on and as of the date of this Agreement and as of the Closing Date (other than representations and warranties
that by their terms speak as of another date, which representations and warranties shall be true and correct in all material respects
as of such other date) and (B) the Investor shall have performed in all material respects all obligations required to be performed
by it under this Agreement at or prior to the Closing; and


 


(ii)                the
Company shall have received a certificate signed on behalf of the Investor by an executive officer or principal certifying to the effect
that the conditions set forth in Section 1.1(e)(i) have been satisfied.


 


Section 1.2            Interpretation.
When a reference is made in this Agreement to “Recitals,” “Articles,” “Sections,” “Schedules”
such reference shall be to a Recital, Article or Section of, or Schedule to, this Agreement, unless otherwise indicated.. The
terms defined in the singular have a comparable meaning when used in the plural, and vice versa. References to “herein,” “hereof,”
 “hereunder” and the like refer to this Agreement as a whole and not to any particular section or provision, unless the context
requires otherwise. The headings contained in this Agreement are for reference purposes only and are not part of this Agreement. Whenever
the words “include,” “includes” or “including” are used in this Agreement, they shall be deemed followed
by the words “without limitation.” No rule of construction against the draftsperson shall be applied in connection with
the interpretation or enforcement of this Agreement, as this Agreement is the product of negotiation between sophisticated parties advised
by counsel. All references to “$” or “dollars” mean the lawful currency of the United States of America. Except
as expressly stated in this Agreement, all references to any statute, rule or regulation are to the statute, rule or regulation
as amended, modified, supplemented or replaced from time to time (and, in the case of statutes, include any rules and regulations
promulgated under the statute) and to any section of any statute, rule or regulation include any successor to the section. References
to a “business day” shall mean any day except Saturday, Sunday and any day on which banking institutions in the State of New
York generally are authorized or required by law or other governmental actions to close.


 


ARTICLE II


 


EXCHANGE


 


Section 2.1            Exchange.
On the terms and subject to the conditions set forth in this Agreement, upon the Closing (i) the Company agrees to issue to the Investor,
in exchange for the 150,000 Exchanged Shares, 150,000 Series A Preferred Shares, and (ii) the Investor agrees to deliver to
the Company certificate(s) or book-entry shares representing the Exchanged Shares.


 


Section 2.2            Exchange
Documentation. Settlement of the Exchange will take place on the Closing Date, at which time the Investor will cause delivery
of the Exchanged Shares to the Company or its designated agent and the Company will cause delivery of the Series A Preferred Shares
to the Investor.


 


Section 2.3            Status
of Preferred Shares after Closing. The Exchanged Shares exchanged for the Series A Preferred Shares pursuant to this Article II
are being reacquired by the Company and shall have the status of authorized but unissued Common Shares and may be issued or reissued.


 






     


     


    

 


Section 2.4            Securities
Act Exemption. The Exchange is being effected pursuant to an exemption from registration under the Securities Act, including but
not limited to Section 3(a)(9) thereof.


 


ARTICLE III


 


Right
of first OFFER


 


Section 3.1            Definitions.
With respect to this Article III, the following capitalized terms shall have the meaning therein set forth:


 


		(a)	“Company Notice” means written notice from the Company notifying the selling Investor
that the Company intends to exercise its Right of First Offer as to some or all of the Subject Shares with respect to any Proposed Transfer.



 


		(b)	“Proposed Transfer” means any assignment, sale, offer to sell, pledge, mortgage, hypothecation,
encumbrance, disposition of or any other like transfer or encumbering of any Subject Shares (or any interest therein) proposed by the
Investor.



 


		(c)	“Proposed Transfer Notice” means written notice from the Investor setting forth the
terms and conditions of a Proposed Transfer.



 


		(d)	“Right of First Offer” means the right, but not an obligation, of the Company, or its
permitted transferees or assigns, to purchase some or all of the Subject Shares with respect to a Proposed Transfer, at the price set
forth in the Proposed Transfer Notice.



 


		(e)	“Subject Shares” means the Series A Preferred Shares and the Common Shares into which they may be converted
pursuant to their terms.



 


Section 3.2           Grant.
Subject to the terms set forth herein, in the event the Investor proposes to undertake a Proposed Transfer, the Investor must comply with
the terms of Section 3.2 hereof.


 


Section 3.2           Notice
and Exercise. The Investor, upon proposing to make a Proposed Transfer must deliver a Proposed Transfer Notice to the Company
not later than thirty (30) days prior to the commencement of such Proposed Transfer. Such Proposed Transfer Notice shall contain the price
at which the Investor is willing to undertake the Proposed Transfer and the number of Subject Shares the Investor is willing to sell as
part of the Proposed Transfer. The Company shall then have the right, but not the obligation, to purchase some or all of the Subject Shares
that are the subject of the Proposed Transfer Notice. To exercise its Right of First Offer and purchase all or any part of the Subject
Shares listed in the Proposed Transfer Notice, the Company must deliver a Company Notice to the Investor within ten (10) days after
delivery of the Proposed Transfer Notice stating the number of Subject Shares the Company is willing to purchase. If the Company does
not exercise its Right of First Offer within the time allowed under this Subsection for such exercise, elects to purchase some, but not
all, of the Subject Shares which are the subject of the Proposed Transfer Notice, or fails to purchase the Subject Shares which are the
subject of the Company Notice in accordance with this subsection, the Investor shall be free, following the expiration of such time for
exercise or such failure to purchase pursuant to any exercise, to sell the Subject Shares specified in such Proposed Transfer Notice,
or those Subject Shares specified in the Proposed Transfer Notice which are not accepted for purchase by the Company in the Company Notice,
on terms no less favorable to the Investor than the terms specified in such Proposed Transfer Notice. Investor shall promptly disclose
in writing to the Company the price at which any such Subject Shares were ultimately sold. Any Proposed Transfer by the Investor that
would be on terms less favorable to the Investor than the terms specified in the Proposed Transfer Notice shall be subject to Section 3.2
and require a new Proposed Transfer Notice before the Proposed Transfer can be undertaken.


 


Section 3.3           Consideration;
Closing. If the consideration proposed to be paid for the Subject Shares is in property, services or other non-cash consideration,
the fair market value of the consideration shall be as determined reasonably and in good faith by the Company’s Board of Directors
and as set forth in the Company Notice. If the Company cannot for any reason pay for the Subject Shares in the same form of non-cash consideration,
the Company may pay the cash value equivalent thereof, as determined reasonably and in good faith by the Board of Directors and as set
forth in the Company Notice. The closing of the purchase of Subject Shares by the Company shall take place, and all payments from the
Company shall have been delivered to the Investor, by the later of (i) the date specified in the Proposed Transfer Notice as the
intended date of the Proposed Transfer and (ii) thirty (30) days after delivery of the Proposed Transfer Notice.


 






     


     


    

 


Section 3.4            Effect
of Failure to Comply.


 


(a)            Transfer
Void; Equitable Relief. Any Proposed Transfer not made in compliance with the requirements of this Article III shall be null
and void ab initio, shall not be recorded on the books of the Company or its transfer agent and shall not be recognized by the Company.
Each party hereto acknowledges and agrees that any breach of this Article III would result in substantial harm to the other party
hereto for which monetary damages alone could not adequately compensate. Therefore, the parties hereto unconditionally and irrevocably
agree that any non-breaching party hereto shall be entitled to seek protective orders, injunctive relief and other remedies available
at law or in equity (including, without limitation, seeking specific performance or the rescission of purchases, sales and other transfers
of Subject Shares not made in strict compliance with this Agreement).


 


(b)            Violation
of First Offer Right. If the Investor becomes obligated to sell any Subject Shares to the Company under this Agreement and fails to
deliver such Subject Shares in accordance with the terms of this Agreement, the Company may, at its option, in addition to all other remedies
it may have, send to the Investor the purchase price for such Subject Shares as is herein specified and transfer to the name of the Company
on the Company’s books any certificates, instruments, or book entry representing the Subject Shares to be sold.


 


Section 3.5            Prohibited
Transferees.  Notwithstanding the foregoing, the Holder shall not transfer any Exchange
Shares to any entity which, in the reasonable determination of the Company’s Board of Directors, directly or indirectly competes
with the Company or its subsidiaries.


 


ARTICLE IV


 


REPRESENTATIONS AND WARRANTIES OF THE COMPANY


 


The Company represents and warrants to the Investor
as of the date hereof and as of the Closing Date:


 


Section 4.1            Existence
and Power.


 


(a)            Organization,
Authority and Significant Subsidiaries. The Company is duly organized, validly existing and in good standing under the laws of the
State of New York and has all necessary power and authority to own, operate and lease its properties and to carry on its business in all
material respects as it is being currently conducted, and except as has not and would not in the reasonable judgment of the Company be
expected to be material to the Company or any of its Subsidiaries, has been duly qualified as a foreign corporation for the transaction
of business and is in good standing under the laws of each other jurisdiction in which it owns or leases properties or conducts any business
so as to require such qualification. Each subsidiary of the Company that is a “significant subsidiary” within the meaning
of Rule 1-02(w) of Regulation S-X under the Securities Act of 1933, as amended (each, a “Subsidiary”), including,
without limitation, Hanover Community Bank, has been duly organized and is validly existing in good standing under the laws of its jurisdiction
of organization. The certificate of incorporation and bylaws of the Company, copies of which have been available to the Investor prior
to the date hereof, are true, complete and correct copies of such documents as in full force and effect as of the date hereof.


 


(b)           Capitalization.
The authorized capital stock of the Company consists of 32,000,000 shares, of which (i) 17,000,000 shares are designated as Common
Shares, of which 7,285,648 shares are issued and outstanding as of the date hereof (the “Capitalization Date”) and
(ii) 15,000,000 shares are designated as preferred shares, of which (A) 150,000 were designated as the “SERIES A CONVERTIBLE
PERPETUAL PREFERRED STOCK” and none of which were issued and outstanding as of the Capitalization Date. The outstanding shares of
capital stock of the Company have been duly authorized and are validly issued and outstanding, fully paid and non-assessable, and subject
to no preemptive rights (and were not issued in violation of any preemptive rights), and have been issued in compliance with applicable
securities laws. As of the date hereof, the Company does not have outstanding any securities or other obligations providing the holder
the right to acquire Common Shares or Series A Preferred Shares that are not reserved for issuance, and the Company has not made
any other commitment to authorize, issue or sell any Common Shares or Series A Preferred Shares except pursuant to this Agreement
or pursuant to equity awards outstanding.


 






     


     


    

 


Section 4.2           Authorization
and Enforceability.


 


(a)           The
Company has the corporate power and authority to execute and deliver this Agreement and to carry out its obligations hereunder, which
includes the issuance of the Series A Preferred Shares .


 


(b)           The
execution, delivery and performance by the Company of this Agreement and the consummation of the transactions contemplated hereby have
been duly authorized by all necessary corporate action on the part of the Company, and no further approval or authorization is required
on the part of the Company. This Agreement is a valid and binding obligation of the Company enforceable against the Company in accordance
with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium and similar laws affecting creditors’ rights
and remedies generally, and to general principles of equity, including principles of commercial reasonableness, good faith and fair dealing
(regardless of whether enforcement is sought in a proceeding at law or in equity) (the “Bankruptcy Exceptions”).


 


Section 4.3            Series A
Preferred Shares . The Series A Preferred Shares have been duly and validly authorized by all necessary action, and, when
issued and delivered pursuant to this Agreement, such Series A Preferred Shares will be duly and validly issued and fully paid and
non-assessable free and clear of any liens or encumbrances, will not be issued in violation of any preemptive rights, and will not subject
the holder thereof to personal liability.


 


Section 4.4            Non-Contravention.


 


(a)           The
execution, delivery and performance by the Company of this Agreement and the consummation of the transactions contemplated hereby, and
compliance by the Company with the provisions hereof, will not (i) violate, conflict with, or result in a breach of any provision
of, or constitute a default (or an event which, with notice or lapse of time or both, would constitute a default) under, or result in
the termination of, or accelerate the performance required by, or result in a right of termination or acceleration of, or result in the
creation of, any lien, security interest, charge or encumbrance upon any of the properties or assets of the Company or any Company Subsidiary
under any of the terms, conditions or provisions of (A) its organizational documents or (B) any note, bond, mortgage, indenture,
deed of trust, license, lease, agreement or other instrument or obligation to which the Company or any Company Subsidiary is a party or
by which it or any Company Subsidiary may be bound, or to which the Company or any Company Subsidiary or any of the properties or assets
of the Company or any Company Subsidiary may be subject, or (ii) subject to compliance with the statutes and regulations referred
to in the next paragraph, violate any statute, rule or regulation or any judgment, ruling, order, writ, injunction or decree applicable
to the Company or any Company Subsidiary or any of their respective properties or assets except, in the case of clauses (i)(B) and
(ii), for those occurrences that, individually or in the aggregate, would not reasonably be expected to be material to the Company or
any of its Subsidiaries.


 


(b)           Other
than the filing of any current report on Form 8-K required to be filed with the Securities and Exchange Commission (“SEC”),
such filings and approvals as are required to be made or obtained under any state “blue sky” laws, and such consents and approvals
that have been made or obtained, no notice to, filing with or review by, or authorization, consent or approval of, any Governmental Entity
is required to be made or obtained by the Company in connection with the consummation by the Company of the Exchange except for any such
notices, filings, reviews, authorizations, consents and approvals the failure of which to make or obtain would not, individually or in
the aggregate, reasonably be expected to be material to the Company.


 


Section 4.5            Anti-Takeover
Provisions. The consummation of the transactions contemplated by this Agreement will not be subject to any “moratorium,”
 “control share,” “fair price,” “interested stockholder” or other anti- takeover laws and regulations
of the State of New York.


 






     


     


    

 


Section 4.6            No
Material Adverse Effect. With the exception of any impacts that may result from the current coronavirus (COVID-19) pandemic, since
August 12, 2022, no fact, circumstance, event, change, occurrence, condition or development has occurred that, individually or in
the aggregate, has had or would reasonably be expected to have a material adverse effect upon the Company, its results of operations or
prospects.


 


 


Section 4.7            Offering
of Securities. Neither the Company nor any person acting on its behalf has taken any action (including any offering of any securities
of the Company under circumstances which would require the integration of such offering with the issuance of the Series A Preferred
Shares under the Securities Act and the rules and regulations of the SEC promulgated thereunder), which would reasonably be expected
to subject the issuance of the Series A Preferred Shares to the Investor pursuant to this Agreement to the registration requirements
of the Securities Act.


 


Section 4.8           Brokers
and Finders. No broker, finder or investment banker is entitled to any financial advisory, brokerage, finder’s or other
fee or commission in connection with this Agreement or the transactions contemplated hereby based upon arrangements made by or on behalf
of the Company or any Subsidiary for which the Investor could have any liability.


 


ARTICLE V


 


REPRESENTATIONS AND WARRANTIES OF INVESTOR


 


The Investor represents and warrants to the Company
as of the date hereof and as of the Closing Date:


 


Section 5.1            Organization;
Authority. The Investor is an entity, duly organized, validly existing and in good standing under the laws of the jurisdiction
of its organization with the requisite power and authority to enter into and to consummate the transactions contemplated by this Agreement
and otherwise to carry out its obligations hereunder. The execution, delivery and performance by the Investor of this Agreement and the
consummation of the transactions contemplated hereby have been duly authorized by all necessary action on the part of the Investor, and
no further approval or authorization is required on the part of the Investor. This Agreement has been duly and validly executed and delivered
by the Investor. Assuming due authorization, execution and delivery by Company, this Agreement constitutes the legal, valid and binding
obligation of the Investor, enforceable against the Investor in accordance with its terms and conditions, except as enforceability may
be limited by the Bankruptcy Exception.


 


Section 5.2            Non
Contravention.


 


(a)           The
execution, delivery and performance by the Investor of this Agreement and the consummation of the transactions contemplated hereby, and
compliance by the Investor with the provisions hereof, will not (i) violate, conflict with, or result in a breach of any provision
of, or constitute a default (or an event which, with notice or lapse of time or both, would constitute a default) under, or result in
the termination of, or accelerate the performance required by, or result in a right of termination or acceleration of, or result in the
creation of, any lien, security interest, charge or encumbrance upon any of the properties or assets of the Investor under any of the
terms, conditions or provisions of (A) its organizational documents or (B) any note, bond, mortgage, indenture, deed of trust,
license, lease, agreement or other instrument or obligation to which the Investor is a party or by which it may be bound, or to which
the Investor or any of the properties or assets of the Investor may be subject, or (ii) violate any statute, rule or regulation
or any judgment, ruling, order, writ, injunction or decree applicable to the Investor or any of its properties or assets except, in the
case of clauses (i)(B) and (ii), for those occurrences that, individually or in the aggregate, have not had and would not reasonably
be expected to have a material adverse effect on the ability of the Investor to consummate the transactions contemplated by this Agreement.


 


(b)           Other
than such consents and approvals that have been made or obtained, no notice to, filing with or review by, or authorization, consent or
approval of, any governmental entity is required to be made or obtained by the Investor in connection with the consummation by the Investor
of the Exchange.


 






     


     


    

 


ARTICLE VI


 


COVENANTS


 


Section 6.1            Commercially
Reasonable Efforts. Subject to the terms and conditions of this Agreement, each of the parties will use its commercially reasonable
efforts in good faith to take, or cause to be taken, all actions, and to do, or cause to be done, all things necessary, proper or desirable,
or advisable under applicable law, so as to permit consummation of the Exchange, as promptly as practicable and otherwise to enable consummation
of the transactions contemplated hereby and shall use commercially reasonable efforts to cooperate with the other party to that end.


 


Section 6.2           Certain
Notifications Until Closing. From the date hereof until the Closing, the Company shall promptly notify the Investor of (a) any
fact, event or circumstance of which it is aware and which would reasonably be likely to cause any representation or warranty of the Company
contained in this Agreement to be untrue or inaccurate in any material respect or to cause any covenant or agreement of the Company contained
in this Agreement not to be complied with or satisfied in any material respect, (b) any action or proceeding pending or, to the knowledge
of such party, threatened against such party that questions or might question the validity of this Agreement or seeks to enjoin or otherwise
restrain the transactions contemplated hereby, and (c) with respect to the Company, any fact, circumstance, event, change, occurrence,
condition or development of which the Company is aware and which, individually or in the aggregate, has had or would reasonably be expected
to have a material adverse effect; provided, however, that delivery of any notice pursuant to this Section 6.2 shall not limit or
affect any rights of or remedies available to the Investor.


 


ARTICLE VII


 


ADDITIONAL AGREEMENTS


 


Section 7.1            Unregistered
Series A Preferred Shares . The Investor acknowledges that the Series A Preferred Shares have not been registered under
the Securities Act or under any state securities laws. The Investor is acquiring the Series A Preferred Shares pursuant to an exemption
from registration under the Securities Act, including but not limited to Section 3(a)(9) thereof.


 


Section 7.2            Legend.
The Investor and the Company agree that all certificates or other instruments representing the Series A Preferred Shares will not
bear a legend other than a legend referencing the provisions of Article III hereof.


 


Section 7.3            Certain
Transactions. The Company will not merge or consolidate with, or sell, transfer or lease all or substantially all of its property
or assets to, any other party unless the successor, transferee or lessee party (or its ultimate parent entity), as the case may be (if
not the Company), assumes the due and punctual performance and observance of each and every covenant, agreement and condition of this
Agreement to be performed and observed by the Company.


 


Section 7.4             Transfer
of Series A Preferred Shares . Subject to Article III and compliance with applicable securities laws, the Investor shall
be permitted to transfer, sell, assign or otherwise dispose of (“Transfer”) all or a portion of the Series A Preferred
Shares at any time, and the Company shall take all steps as may be reasonably requested by the Investor to facilitate the Transfer of
the Series A Preferred Shares .


 


ARTICLE VIII


 


MISCELLANEOUS


 


Section 8.1            Termination.
This Agreement may be terminated at any time prior to the Closing:


 


(a)            by
either the Investor or the Company if the Closing shall not have occurred by December 31, 2022; provided, however, that in the event
the Closing has not occurred by such date, the parties will consult in good faith to determine whether to extend the term of this Agreement,
it being understood that the parties shall be required to consult only until the fifth day after such date and not be under any obligation
to extend the term of this Agreement thereafter; provided, further, that the right to terminate this Agreement under this Section 8.1(a) shall
not be available to any party whose breach of any representation or warranty or failure to perform any obligation under this Agreement
shall have caused or resulted in the failure of the Closing to occur on or prior to such date;


 






     


     


    

 


(b)           by
either the Investor or the Company in the event that any governmental entity shall have issued an order, decree or ruling or taken any
other action restraining, enjoining or otherwise prohibiting the transactions contemplated by this Agreement (or if any such governmental
entity informs the Investor or the Company that it intends to disapprove any notice or application required to be filed by such party
in order to consummate the transactions contemplated by this Agreement) and such order, decree, ruling or other action shall have become
final and non-appealable; or


 


(c)            by
the mutual written consent of the Investor and the Company.


 


In the event of termination of this Agreement
as provided in this Section 8.1, this Agreement shall forthwith become void and there shall be no liability on the part of either
party hereto except that nothing herein shall relieve either party from liability for fraud, willful misconduct or any breach of this
Agreement.


 


Section 8.2            Survival
of Representations and Warranties. The representations and warranties of the Company and the Investor made herein or in any certificates
delivered in connection with the Closing shall not survive the Closing.


 


Section 8.3           Amendment.
No amendment of any provision of this Agreement will be effective unless made in writing and signed by an officer or a duly authorized
representative of each of the Company and the Investor. No failure or delay by any party in exercising any right, power or privilege hereunder
shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise of any other
right, power or privilege. The rights and remedies herein provided shall be cumulative of any rights or remedies provided by law.


 


Section 8.4            Waiver
of Conditions. The conditions to each party’s obligation to consummate the Exchange are for the sole benefit of such party
and may be waived by such party in whole or in part to the extent permitted by applicable Law. No waiver will be effective unless it is
in a writing signed by a duly authorized officer of the waiving party that makes express reference to the provision or provisions subject
to such waiver.


 


Section 8.5            Governing
Law; Submission to Jurisdiction, etc. All questions concerning the construction, validity, enforcement and interpretation
of this Agreement shall be governed by and construed in accordance with the internal laws of the State of New York applicable to contracts
made and to be performed entirely within such State. Each party agrees that all proceedings concerning the interpretation, enforcement
and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective affiliates, employees
or agents) shall be resolved in the New York courts. Each party hereto hereby irrevocably submits to the non-exclusive jurisdiction of
the New York courts for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein (including with respect to the enforcement of this Agreement), and hereby irrevocably waives, and agrees not to assert
in any proceeding, any claim that it is not personally subject to the jurisdiction of any such New York court, or that such proceeding
has been commenced in an improper or inconvenient forum. Each party hereto hereby irrevocably waives personal service of process and consents
to process being served in any such proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with
evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall
constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any
right to serve process in any manner permitted by law. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED
BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS
CONTEMPLATED HEREBY.


 






     


     


    

 


Section 8.6            Notices.
Any notice, request, instruction or other document to be given hereunder by any party to the other will be in writing and will be deemed
to have been duly given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered
via facsimile or e-mail (provided the sender receives a machine-generated confirmation of successful facsimile transmission or e-mail
notification or confirmation of receipt of an e-mail transmission) at the facsimile number or e-mail address specified in this Section 8.6
prior to 5:00 p.m., Eastern time, on a Business Day, (b) the next Business Day after the date of transmission, if such notice or
communication is delivered via facsimile or e-mail at the facsimile number or e-mail address specified in this Section 8.6 on a day
that is not a Business Day or later than 5:00 p.m., Eastern time, on any Business Day, (c) if sent by U.S. nationally recognized
overnight courier service with next day delivery specified (receipt requested) the Business Day following delivery to such courier service,
or (d) upon actual receipt by the party to whom such notice is required to be given. All notices hereunder shall be delivered as
set forth below or pursuant to such other instructions as may be designated in writing by the party to receive such notice.


 


If to the Company:


 


Hanover Bancorp, Inc.


80 East Jericho Turnpike


Mineola, NY 11501


Attention: Michael P. Puorro


Facsimile:


Email: mpuorro@hanoverbank.com


 


With a copy to:


 


Windels Marx Lane & Mittendorf, LLP


120 Albany Street Plaza FL 6


New Brunswick NJ 08901


Attention: Robert A. Schwartz


Facsimile: (732) 846-8877


Email: rschwartz@windelsmarx.com


 


If to the Investor:


 


Castle Creek Capital Partners VIII, LP


c/o Castle Creek Capital LLC


6051 El Tordo, P.O. Box 1329


Rancho Santa Fe, California 92067


Attention: Tony Scavuzzo, Principal


Telephone: (858) 756-8300


Facsimile: (858) 756-8301


Email: tscavuzzo@castlecreek.com


 


With a copy to:


 


Sidley Austin LLP


1999 Avenue of the Stars, 17th Floor


Los Angeles, CA 90067


Attention: Vijay S. Sekhon, Esq.


Telephone: (310) 595-9507


Facsimile: (310) 595-9501


Email: vsekhon@sidley.com


 


Section 8.7            Assignment.
Neither this Agreement nor any right, remedy, obligation nor liability arising hereunder or by reason hereof shall be assignable by any
party hereto without the prior written consent of each other party, and any attempt to assign any right, remedy, obligation or liability
hereunder without such consent shall be void, except an assignment, in the case of a Business Combination, where such party is not the
surviving entity, or a sale of substantially all of its assets, to the entity which is the survivor of such Business Combination or the
purchaser in such sale subject to compliance with Section 7.3. The term “Business Combination” means a merger,
consolidation, statutory share exchange or similar transaction that requires the approval of the Company’s stockholders.


 






     


     


    

 


Section 8.8            Severability.
If any provision of this Agreement, or the application thereof to any person or circumstance, is determined by a court of competent jurisdiction
to be invalid, void or unenforceable, the remaining provisions hereof, or the application of such provision to persons or circumstances
other than those as to which it has been held invalid or unenforceable, will remain in full force and effect and shall in no way be affected,
impaired or invalidated thereby, so long as the economic or legal substance of the transactions contemplated hereby is not affected in
any manner materially adverse to any party. Upon such determination, the parties shall negotiate in good faith in an effort to agree upon
a suitable and equitable substitute provision to effect the original intent of the parties.


 


Section 8.9            No
Third-Party Beneficiaries. Nothing contained in this Agreement, expressed or implied, is intended to confer upon any person or
entity other than the Company and the Investor any benefit, right or remedies.


 


Section 8.10          Entire
Agreement, etc.  This Agreement (including the Schedules hereto) constitutes the entire agreement, and supersedes all
other prior agreements, understandings, representations and warranties, both written and oral, between the parties, with respect to the
subject matter hereof. For the avoidance of doubt, the Purchase Agreement shall remain in full force and effect, but shall be deemed amended
hereby, and any provisions in this Agreement that supplement, duplicate or contradict any provision of the Purchase Agreement shall be
deemed to supersede the corresponding provision of the Purchase Agreement from and after the effective date hereof.


 


Section 8.11          Counterparts
and Facsimile.  For the convenience of the parties hereto, this Agreement may be executed in any number of separate counterparts,
each such counterpart being deemed to be an original instrument, and all such counterparts will together constitute the same agreement.
Executed signature pages to this Agreement may be delivered by electronic transmission or facsimile and such electronic transmissions
and facsimiles will be deemed as sufficient as if actual signature pages had been delivered.


 


Section 8.12          Specific
Performance.  The parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement
were not performed in accordance with their specific terms. It is accordingly agreed that the parties shall be entitled (without the necessity
of posting a bond) to specific performance of the terms hereof, this being in addition to any other remedies to which they are entitled
at law or equity.


 


Section 8.13          Expenses.
Except as otherwise expressly provided  in  this  Agreement,  all  costs  and expenses incurred in connection
with this Agreement will be borne and paid by the party incurring the expense.


 


[Remainder of Page Intentionally Left
Blank]


 






     


     


    

 


IN WITNESS WHEREOF, the parties
hereto have caused this Agreement to be duly executed by their respective authorized officers as of the day and year first above written.


 


	 	Hanover Bancorp, Inc.
	 	 	 
	 	By:	/s/  Michael P. Puorro
	 	Name:	Michael P. Puorro
	 	Title:	Chairman and Chief Executive Officer
	 	 	 
	 	 	 
	 	CASTLE CREEK CAPITAL PARTNERS VIII, LP
	 	 	 
	 	By:	/s/ Tony Scavuzzo
	 	Name:	Tony Scavuzzo
	 	Title:	Principal


 


[Signature Page to Exchange Agreement}